UK markets open in 5 hours 57 minutes

Genmab A/S (0MGB.L)

LSE - LSE Delayed price. Currency in DKK
Add to watchlist
2,581.26-9.88 (-0.38%)
At close: 06:18PM BST
Full screen
Previous close2,591.14
Open2,567.00
BidN/A x N/A
AskN/A x N/A
Day's range2,559.00 - 2,574.00
52-week range2,379.00 - 3,325.00
Volume3,075
Avg. volume14,977
Market capN/A
Beta (5Y monthly)0.78
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date02 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Genmab Announces Financial Results for the First Quarter of 2024

    May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024An additional Phase

  • Business Wire

    FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

    NEW YORK & COPENHAGEN, Denmark, April 29, 2024--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

  • Globe Newswire

    TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

    Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; April 30, 2024 – Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tf